Navigation Links
BD Supports the FDA's Proposal to Reclassify Rapid Influenza Tests
Date:8/26/2013

FRANKLIN LAKES, N.J., Aug. 26, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, supports the U.S. Food and Drug Administration's (FDA's) proposed reclassification of rapid influenza detection tests.  A hearing, held on June 13th by FDA's CDRH Microbiology Devices Advisory Committee Meeting, examined the FDA's proposal to reclassify rapid influenza detection tests (RIDTs) currently regulated as Class I devices, into Class II devices.

The recent 2009 flu pandemic has emphasized the poor performance of point-of-care flu tests available at the time. The new performance standards will provide healthcare providers with criteria for evaluating the tests that they use. The proposal would increase performance requirements for RIDTs to attain at least a sensitivity of 90 percent for influenza A and 80 percent for influenza B versus viral culture and/or 80 percent versus polymerase chain reaction (PCR) methods. If these minimum clinical performance criteria are not met, marketed devices will need to be withdrawn from the market one year after the rule is finalized. This proposal culminates years of publications showing that many of the visual read RIDTs had poor sensitivity when compared to viral culture and to reverse transcription PCR methods.

"This proposal is a step in the right direction as physicians and hospitals routinely rely on rapid diagnostic influenza tests to help manage patients that are suspected of having influenza," said Tom Polen, President, BD Diagnostics – Diagnostic Systems. "Raising the standards of rapid influenza tests will provide healthcare providers the right information to guide patient diagnosis and treatment without requiring repeat testing."

BD pioneered the development of a higher performing test
'/>"/>

SOURCE BD-Becton Dickinson
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
2. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
3. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
4. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
5. New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
6. Ventana Supports World Patient Safety Day, July 25
7. eCardio Supports the Carolinas HealthCare Foundation Through Grant for Heart Of A Champion Day
8. Verify Brand Supports the Proposed FDA Unique Device Identification (UDI) System for Medical Devices
9. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
10. Henry Schein Cares Supports Alliance for Oral Health Across Borders Leadership Event
11. Cardinal Health Supports Future Pharmacists With Nearly $1 Million In Scholarships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  NeuroSigma, Inc. (NeuroSigma), ... focused on commercialization of its non-invasive Monarch ... and neuropsychiatric disorders, today announced that enrollment has begun ... nerve stimulation (eTNS) as adjunctive therapy for the treatment ... being conducted at the Olive View-UCLA Medical Center in ...
(Date:7/22/2014)... York , July 22, 2014 ... Partnerschaft für umfassenden Schutz von Pharmazeuten ... Österreich    Equashield ( ... Transfersystemen (Closed System Transfer Devices, CSTDs) für gefährliche ... einen Vertriebshändler und Hersteller von medizinischen ...
(Date:7/21/2014)... McCord Research, Inc. was recently granted ... This patent describes a method for accelerating wound ... inventor, Dr. McCord, this method includes administering or ... composition of an effective amount of hydroxytyrosol and ... such that the administration of the combination reduces ...
Breaking Medicine Technology:Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2
... well-tolerated with signs of durable,disease control in advanced ... /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. today presented preliminary results ... trial (DC-MEL-202). The,results showed that UVIDEM was well ... response in patients with,progressive metastatic melanoma. , The ...
... trial presented at ENDO 2007 , ,- Regulatory approvals ... recruitment in Europe , ,MONTREAL, QUEBEC -- (MARKET WIRE) ... that 26-week data from,its first Phase 3 study testing ... ENDO, the 89th,annual meeting of the Endocrine Society. The ...
Cached Medicine Technology:IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5Theratechnologies: TH9507 Phase 3 Clinical Update 2Theratechnologies: TH9507 Phase 3 Clinical Update 3
(Date:7/22/2014)... July 22, 2014 The Pennsylvania ... ) in the Philadelphia Court of ... punitive damages in cases alleging the medication caused ... Liebhard LLP reports. In an Order dated July ... plaintiffs’ request to certify the matter for an ...
(Date:7/22/2014)... The park is the heart of a community. ... made a recent investment in outdoor recreation and ... playground equipment from American Parks Company™. , The community ... is a 475-unit community that was established in the ... a tropical paradise with lush shade trees, green-edged walking ...
(Date:7/22/2014)... of the largest studies ever conducted into the genetic ... sites on chromosomes that harbor inherited genes tied to ... of researchers, now bring the total number of common ... Although these schizophrenia-associated genes aren,t specific enough to ... or will not develop the illness, researchers say they ...
(Date:7/22/2014)... school lacrosse players are facing an increasing number of ... study finds. Although the most common injuries are ... researchers report. They note a better understanding of why ... to protect student athletes. "Concern over concussions in ... learn more about these injuries," said study co-author Dawn ...
(Date:7/22/2014)... CarePoint Health is pleased to announce that Dr. ... the medical staff at Bayonne Medical Center. The election marks ... voted on by the physicians on staff. The office of ... to the administration at Bayonne Medical Center. Dr. Levine is ... to make the Medical Center the best it can be ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 3Health News:Dr. Howard Levine Elected President of the Medical Staff at Bayonne Medical Center 2
... Medical Innovations, Inc. (Amex: IMA ), a ... solutions, announced today that it will attend the upcoming ... 15, 2009 at the Westin St. Francis Hotel in ... Jon Russell, Vice President, Finance, will attend. Mr. ...
... Corporation (Nasdaq: BPUR ) announced today that ... stating that NASDAQ has again suspended enforcement of its ... listing, thereby extending the Company,s time in which to ... to resume on Monday, April 20, 2009. The Company ...
... Executive with Proven Ability to Develop Companies into ... Growth OpportunitiesFORT LAUDERDALE, Fla., Dec. 30 eDiets.com, ... provider of convenient at-home diet, fitness and healthy ... the company,s new President and CEO, effective immediately. ...
... didn,t halt women,s risk of developing disease , , TUESDAY, ... the supposed cancer-fighting powers of vitamins C and E, ... don,t prevent the disease in women. , And another ... new study found. , , "Simply taking antioxidant supplements ...
... had cancer as well as idiopathic pulmonary fibrosis, study finds ... in a gene previously found to help protect the lungs ... some inherited cases of a lethal lung disease affecting older ... the SFTPA2 gene have been found in families ...
... of adults and 19 percent of children taking chemotherapy drugs ... dose or experienced other mistakes involving their medications, according to ... professor of pediatrics at the University of Massachusetts Medical School, ... Journal of Clinical Oncology . , "As cancer care ...
Cached Medicine News:Health News:Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 13, 2009 2Health News:Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance 2Health News:eDiets.com(R) Appoints Kevin N. McGrath as President and CEO 2Health News:eDiets.com(R) Appoints Kevin N. McGrath as President and CEO 3Health News:Vitamins Fail to Prevent Cancer: Study 2Health News:Vitamins Fail to Prevent Cancer: Study 3Health News:Gene Mutation Tied to Inherited Fatal Lung Disease 2Health News:Errors involving medications common in outpatient cancer treatment 2
... practical, comfortable chair for examination ... height is adjustable from 540 ... use of an independent foot ... through 360 and incorporates a ...
... Halogen HPX Streak Retinoscope ... handle and provides 40% ... conventional scopes and maintains ... which greatly enhances illumination ...
Sandown chair, with hydraulic lift, sliding headrest and armrests with glides. Black vinyl....
3.5v Halogen HPX Spot Retinoscope provides 40% more light output than conventional scopes and maintains a consistent output level which greatly enhances illumination and produces the sharpest retina...
Medicine Products: